ID   A4_MOUSE                Reviewed;         770 AA.
AC   P12023; P97487; P97942; Q99K32;
DT   01-OCT-1989, integrated into UniProtKB/Swiss-Prot.
DT   09-MAY-2003, sequence version 3.
DT   18-JUN-2025, entry version 268.
DE   RecName: Full=Amyloid-beta precursor protein {ECO:0000250|UniProtKB:P05067};
DE   AltName: Full=ABPP;
DE            Short=APP;
DE   AltName: Full=Alzheimer disease amyloid A4 protein homolog;
DE   AltName: Full=Alzheimer disease amyloid protein;
DE   AltName: Full=Amyloid precursor protein {ECO:0000305};
DE   AltName: Full=Amyloid-beta (A4) precursor protein {ECO:0000312|MGI:MGI:88059};
DE   AltName: Full=Amyloid-beta A4 protein {ECO:0000250|UniProtKB:P08592};
DE   AltName: Full=Amyloidogenic glycoprotein;
DE            Short=AG;
DE   Contains:
DE     RecName: Full=N-APP;
DE   Contains:
DE     RecName: Full=Soluble APP-alpha;
DE              Short=S-APP-alpha;
DE   Contains:
DE     RecName: Full=Soluble APP-beta;
DE              Short=S-APP-beta;
DE   Contains:
DE     RecName: Full=C99;
DE     AltName: Full=APP-C99;
DE     AltName: Full=Beta-secretase C-terminal fragment;
DE              Short=Beta-CTF;
DE   Contains:
DE     RecName: Full=Amyloid-beta protein 42;
DE              Short=Abeta42;
DE     AltName: Full=Beta-APP42;
DE   Contains:
DE     RecName: Full=Amyloid-beta protein 40;
DE              Short=Abeta40;
DE     AltName: Full=Beta-APP40;
DE   Contains:
DE     RecName: Full=C83;
DE     AltName: Full=Alpha-secretase C-terminal fragment;
DE              Short=Alpha-CTF;
DE   Contains:
DE     RecName: Full=P3(42);
DE   Contains:
DE     RecName: Full=P3(40);
DE   Contains:
DE     RecName: Full=C80;
DE   Contains:
DE     RecName: Full=Gamma-secretase C-terminal fragment 59;
DE     AltName: Full=APP-C59;
DE     AltName: Full=Amyloid intracellular domain 59;
DE              Short=AID(59);
DE     AltName: Full=Gamma-CTF(59);
DE   Contains:
DE     RecName: Full=Gamma-secretase C-terminal fragment 57;
DE     AltName: Full=APP-C57;
DE     AltName: Full=Amyloid intracellular domain 57;
DE              Short=AID(57);
DE     AltName: Full=Gamma-CTF(57);
DE   Contains:
DE     RecName: Full=Gamma-secretase C-terminal fragment 50;
DE     AltName: Full=Amyloid intracellular domain 50;
DE              Short=AID(50);
DE     AltName: Full=Gamma-CTF(50);
DE   Contains:
DE     RecName: Full=C31;
DE   Flags: Precursor;
GN   Name=App {ECO:0000312|MGI:MGI:88059};
GN   Synonyms=A4 {ECO:0000250|UniProtKB:P05067}, AD1
GN   {ECO:0000250|UniProtKB:P05067};
OS   Mus musculus (Mouse).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Glires; Rodentia; Myomorpha; Muroidea; Muridae;
OC   Murinae; Mus; Mus.
OX   NCBI_TaxID=10090;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM APP695).
RC   TISSUE=Brain;
RX   PubMed=3322280; DOI=10.1016/0006-291x(87)90419-0;
RA   Yamada T., Sasaki H., Furuya H., Miyata T., Goto I., Sakaki Y.;
RT   "Complementary DNA for the mouse homolog of the human amyloid beta protein
RT   precursor.";
RL   Biochem. Biophys. Res. Commun. 149:665-671(1987).
RN   [2]
RP   SEQUENCE REVISION.
RA   Yamada T.;
RL   Submitted (MAR-1988) to the EMBL/GenBank/DDBJ databases.
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM APP695).
RC   STRAIN=BALB/cJ; TISSUE=Brain;
RX   PubMed=1756177; DOI=10.1016/0167-4781(91)90231-a;
RA   de Strooper B., van Leuven F., van den Berghe H.;
RT   "The amyloid beta protein precursor or proteinase nexin II from mouse is
RT   closer related to its human homolog than previously reported.";
RL   Biochim. Biophys. Acta 1129:141-143(1991).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM APP695).
RC   STRAIN=SAMP8; TISSUE=Hippocampus;
RX   PubMed=11235921; DOI=10.1139/o00-094;
RA   Kumar V.B., Vyas K., Franko M., Choudhary V., Buddhiraju C., Alvarez J.,
RA   Morley J.E.;
RT   "Molecular cloning, expression, and regulation of hippocampal amyloid
RT   precursor protein of senescence accelerated mouse (SAMP8).";
RL   Biochem. Cell Biol. 79:57-67(2001).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1-19.
RX   PubMed=1555768; DOI=10.1016/0378-1119(92)90375-y;
RA   Izumi R., Yamada T., Yoshikai S., Sasaki H., Hattori M., Sakai Y.;
RT   "Positive and negative regulatory elements for the expression of the
RT   Alzheimer's disease amyloid precursor-encoding gene in mouse.";
RL   Gene 112:189-195(1992).
RN   [6]
RP   PARTIAL NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM APP770).
RC   TISSUE=Mammary tumor;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 281-380, AND ALTERNATIVE SPLICING.
RC   TISSUE=Brain, and Kidney;
RX   PubMed=2493250; DOI=10.1016/0006-291x(89)92808-8;
RA   Yamada T., Sasaki H., Dohura K., Goto I., Sakaki Y.;
RT   "Structure and expression of the alternatively-spliced forms of mRNA for
RT   the mouse homolog of Alzheimer's disease amyloid beta protein precursor.";
RL   Biochem. Biophys. Res. Commun. 158:906-912(1989).
RN   [8]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 289-364.
RC   STRAIN=CD-1; TISSUE=Placenta;
RX   PubMed=2569710; DOI=10.1093/nar/17.13.5396;
RA   Fukuchi K., Martin G.M., Deeb S.S.;
RT   "Sequence of the protease inhibitor domain of the A4 amyloid protein
RT   precursor of Mus domesticus.";
RL   Nucleic Acids Res. 17:5396-5396(1989).
RN   [9]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 656-737.
RC   STRAIN=129/Sv;
RA   Wragg M.A., Busfield F., Duff K., Korenblat K., Capecchi M., Loring J.F.,
RA   Goate A.M.;
RT   "Introduction of six mutations into the mouse genome using 'Hit and Run'
RT   gene-targeting: introduction of familial Alzheimer's disease mutations into
RT   the mouse amyloid precursor protein gene and humanization of the A-beta
RT   fragment.";
RL   Submitted (DEC-1996) to the EMBL/GenBank/DDBJ databases.
RN   [10]
RP   TISSUE SPECIFICITY OF ALTERNATIVE SPLICED FORMS.
RX   PubMed=8510506; DOI=10.1016/0169-328x(93)90020-p;
RA   Sola C., Mengod G., Ghetti B., Palacios J.M., Triarhou L.C.;
RT   "Regional distribution of the alternatively spliced isoforms of beta APP
RT   RNA transcript in the brain of normal, heterozygous and homozygous weaver
RT   mutant mice as revealed by in situ hybridization histochemistry.";
RL   Brain Res. Mol. Brain Res. 17:340-346(1993).
RN   [11]
RP   INTERACTION WITH KNS2.
RX   PubMed=11144355; DOI=10.1016/s0896-6273(00)00124-0;
RA   Kamal A., Stokin G.B., Yang Z., Xia C.-H., Goldstein L.S.;
RT   "Axonal transport of amyloid precursor protein is mediated by direct
RT   binding to the kinesin light chain subunit of kinesin-I.";
RL   Neuron 28:449-459(2000).
RN   [12]
RP   PHOSPHORYLATION AT TYR-757.
RX   PubMed=11279131; DOI=10.1074/jbc.m100792200;
RA   Zambrano N., Bruni P., Minopoli G., Mosca R., Molino D., Russo C.,
RA   Schettini G., Sudol M., Russo T.;
RT   "The beta-amyloid precursor protein APP is tyrosine-phosphorylated in cells
RT   expressing a constitutively active form of the Abl protoncogene.";
RL   J. Biol. Chem. 276:19787-19792(2001).
RN   [13]
RP   PROTEOLYTIC PROCESSING BY GAMMA SECRETASE, AND INTERACTION WITH APBB1.
RX   PubMed=11553691; DOI=10.1046/j.1471-4159.2001.00516.x;
RA   Cupers P., Orlans I., Craessaerts K., Annaert W., De Strooper B.;
RT   "The amyloid precursor protein (APP)-cytoplasmic fragment generated by
RT   gamma-secretase is rapidly degraded but distributes partially in a nuclear
RT   fraction of neurons in culture.";
RL   J. Neurochem. 78:1168-1178(2001).
RN   [14]
RP   C-TERMINAL PROTEIN-PROTEIN INTERACTION, AND MUTAGENESIS OF TYR-728;
RP   THR-743; TYR-757; ASN-759 AND TYR-762.
RX   PubMed=11517249; DOI=10.1523/jneurosci.21-17-06597.2001;
RA   Matsuda S., Yasukawa T., Homma Y., Ito Y., Niikura T., Hiraki T., Hirai S.,
RA   Ohno S., Kita Y., Kawasumi M., Kouyama K., Yamamoto T., Kyriakis J.M.,
RA   Nishimoto I.;
RT   "C-jun N-terminal kinase (JNK)-interacting protein-1b/islet-brain-1
RT   scaffolds Alzheimer's amyloid precursor protein with JNK.";
RL   J. Neurosci. 21:6597-6607(2001).
RN   [15]
RP   INTERACTION WITH DAB2, AND MUTAGENESIS OF GLY-756; TYR-757; ASN-759;
RP   PRO-760 AND TYR-762.
RX   PubMed=11247302; DOI=10.1034/j.1600-0854.2001.020206.x;
RA   Morris S.M., Cooper J.A.;
RT   "Disabled-2 colocalizes with the LDLR in clathrin-coated pits and interacts
RT   with AP-2.";
RL   Traffic 2:111-123(2001).
RN   [16]
RP   INTERACTION WITH MAPK8IP1, AND PHOSPHORYLATION.
RX   PubMed=11912189; DOI=10.1074/jbc.m108372200;
RA   Taru H., Iijima K., Hase M., Kirino Y., Yagi Y., Suzuki T.;
RT   "Interaction of Alzheimer's beta-amyloid precursor family proteins with
RT   scaffold proteins of the JNK signaling cascade.";
RL   J. Biol. Chem. 277:20070-20078(2002).
RN   [17]
RP   INTERACTION OF CTF PEPTIDES WITH NUMB.
RX   PubMed=12011466; DOI=10.1073/pnas.102192599;
RA   Roncarati R., Sestan N., Scheinfeld M.H., Berechid B.E., Lopez P.A.,
RA   Meucci O., McGlade J.C., Rakic P., D'Adamio L.;
RT   "The gamma-secretase-generated intracellular domain of beta-amyloid
RT   precursor protein binds Numb and inhibits Notch signaling.";
RL   Proc. Natl. Acad. Sci. U.S.A. 99:7102-7107(2002).
RN   [18]
RP   PROTEOLYTIC DEGRADATION BY IDE.
RX   PubMed=12634421; DOI=10.1073/pnas.0230450100;
RA   Farris W., Mansourian S., Chang Y., Lindsley L., Eckman E.A., Frosch M.P.,
RA   Eckman C.B., Tanzi R.E., Selkoe D.J., Guenette S.;
RT   "Insulin-degrading enzyme regulates the levels of insulin, amyloid beta-
RT   protein, and the beta-amyloid precursor protein intracellular domain in
RT   vivo.";
RL   Proc. Natl. Acad. Sci. U.S.A. 100:4162-4167(2003).
RN   [19]
RP   SUBCELLULAR LOCATION, AND FUNCTION.
RX   PubMed=15677459; DOI=10.1074/jbc.m409179200;
RA   Cappai R., Cheng F., Ciccotosto G.D., Needham B.E., Masters C.L.,
RA   Multhaup G., Fransson L.A., Mani K.;
RT   "The amyloid precursor protein (APP) of Alzheimer disease and its paralog,
RT   APLP2, modulate the Cu/Zn-nitric oxide-catalyzed degradation of glypican-1
RT   heparan sulfate in vivo.";
RL   J. Biol. Chem. 280:13913-13920(2005).
RN   [20]
RP   INTERACTION WITH CPEB1.
RX   PubMed=16314516; DOI=10.1128/mcb.25.24.10930-10939.2005;
RA   Cao Q., Huang Y.-S., Kan M.-C., Richter J.D.;
RT   "Amyloid precursor proteins anchor CPEB to membranes and promote
RT   polyadenylation-induced translation.";
RL   Mol. Cell. Biol. 25:10930-10939(2005).
RN   [21]
RP   INTERACTION WITH SORL1.
RX   PubMed=16174740; DOI=10.1073/pnas.0503689102;
RA   Andersen O.M., Reiche J., Schmidt V., Gotthardt M., Spoelgen R., Behlke J.,
RA   von Arnim C.A., Breiderhoff T., Jansen P., Wu X., Bales K.R., Cappai R.,
RA   Masters C.L., Gliemann J., Mufson E.J., Hyman B.T., Paul S.M., Nykjaer A.,
RA   Willnow T.E.;
RT   "Neuronal sorting protein-related receptor sorLA/LR11 regulates processing
RT   of the amyloid precursor protein.";
RL   Proc. Natl. Acad. Sci. U.S.A. 102:13461-13466(2005).
RN   [22]
RP   INTERACTION WITH SORL1.
RX   PubMed=16407538; DOI=10.1523/jneurosci.3882-05.2006;
RA   Spoelgen R., von Arnim C.A., Thomas A.V., Peltan I.D., Koker M., Deng A.,
RA   Irizarry M.C., Andersen O.M., Willnow T.E., Hyman B.T.;
RT   "Interaction of the cytosolic domains of sorLA/LR11 with the amyloid
RT   precursor protein (APP) and beta-secretase beta-site APP-cleaving enzyme.";
RL   J. Neurosci. 26:418-428(2006).
RN   [23]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-441, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Brain, Kidney, Lung, Pancreas, and Testis;
RX   PubMed=21183079; DOI=10.1016/j.cell.2010.12.001;
RA   Huttlin E.L., Jedrychowski M.P., Elias J.E., Goswami T., Rad R.,
RA   Beausoleil S.A., Villen J., Haas W., Sowa M.E., Gygi S.P.;
RT   "A tissue-specific atlas of mouse protein phosphorylation and expression.";
RL   Cell 143:1174-1189(2010).
RN   [24]
RP   INTERACTION WITH NGS1.
RX   PubMed=21084623; DOI=10.1523/jneurosci.4464-10.2010;
RA   Norstrom E.M., Zhang C., Tanzi R., Sisodia S.S.;
RT   "Identification of NEEP21 as a ss-amyloid precursor protein-interacting
RT   protein in vivo that modulates amyloidogenic processing in vitro.";
RL   J. Neurosci. 30:15677-15685(2010).
RN   [25]
RP   SUBCELLULAR LOCATION, AND PROTEOLYTIC CLEAVAGE.
RX   PubMed=23931995; DOI=10.1016/j.neuron.2013.05.035;
RA   Das U., Scott D.A., Ganguly A., Koo E.H., Tang Y., Roy S.;
RT   "Activity-induced convergence of APP and BACE-1 in acidic microdomains via
RT   an endocytosis-dependent pathway.";
RL   Neuron 79:447-460(2013).
RN   [26]
RP   INTERACTION WITH VDAC1.
RX   PubMed=25168729; DOI=10.1016/j.neuroscience.2014.07.079;
RA   Fernandez-Echevarria C., Diaz M., Ferrer I., Canerina-Amaro A., Marin R.;
RT   "Abeta promotes VDAC1 channel dephosphorylation in neuronal lipid rafts.
RT   Relevance to the mechanisms of neurotoxicity in Alzheimer's disease.";
RL   Neuroscience 278:354-366(2014).
RN   [27]
RP   SUBCELLULAR LOCATION.
RX   PubMed=25592972; DOI=10.15252/emmm.201404438;
RA   Kizuka Y., Kitazume S., Fujinawa R., Saito T., Iwata N., Saido T.C.,
RA   Nakano M., Yamaguchi Y., Hashimoto Y., Staufenbiel M., Hatsuta H.,
RA   Murayama S., Manya H., Endo T., Taniguchi N.;
RT   "An aberrant sugar modification of BACE1 blocks its lysosomal targeting in
RT   Alzheimer's disease.";
RL   EMBO Mol. Med. 7:175-189(2015).
RN   [28]
RP   TISSUE SPECIFICITY.
RX   PubMed=25757569; DOI=10.1096/fj.14-261453;
RA   Suh J., Moncaster J.A., Wang L., Hafeez I., Herz J., Tanzi R.E.,
RA   Goldstein L.E., Guenette S.Y.;
RT   "FE65 and FE65L1 amyloid precursor protein-binding protein compound null
RT   mice display adult-onset cataract and muscle weakness.";
RL   FASEB J. 29:2628-2639(2015).
RN   [29]
RP   SUBCELLULAR LOCATION, TISSUE SPECIFICITY, DEVELOPMENTAL STAGE, AND
RP   INDUCTION BY HIGH-FAT DIET.
RX   PubMed=26260791; DOI=10.1074/jbc.m115.655076;
RA   Satoh K., Abe-Dohmae S., Yokoyama S., St George-Hyslop P., Fraser P.E.;
RT   "ATP-binding cassette transporter A7 (ABCA7) loss of function alters
RT   Alzheimer amyloid processing.";
RL   J. Biol. Chem. 290:24152-24165(2015).
RN   [30]
RP   INTERACTION WITH LRRK2, SUBCELLULAR LOCATION, TISSUE SPECIFICITY, AND
RP   PHOSPHORYLATION AT THR-743.
RX   PubMed=28720718; DOI=10.1126/scisignal.aam6790;
RA   Chen Z.C., Zhang W., Chua L.L., Chai C., Li R., Lin L., Cao Z.,
RA   Angeles D.C., Stanton L.W., Peng J.H., Zhou Z.D., Lim K.L., Zeng L.,
RA   Tan E.K.;
RT   "Phosphorylation of amyloid precursor protein by mutant LRRK2 promotes AICD
RT   activity and neurotoxicity in Parkinson's disease.";
RL   Sci. Signal. 10:0-0(2017).
RN   [31]
RP   INTERACTION WITH SYT7.
RX   PubMed=30429473; DOI=10.1038/s41467-018-06813-x;
RA   Barthet G., Jorda-Siquier T., Rumi-Masante J., Bernadou F., Mueller U.,
RA   Mulle C.;
RT   "Presenilin-mediated cleavage of APP regulates synaptotagmin-7 and
RT   presynaptic plasticity.";
RL   Nat. Commun. 9:4780-4780(2018).
RN   [32] {ECO:0007744|PDB:2ROZ}
RP   STRUCTURE BY NMR OF 739-770, AND INTERACTION WITH APBB2.
RX   PubMed=18650440; DOI=10.1074/jbc.m803892200;
RA   Li H., Koshiba S., Hayashi F., Tochio N., Tomizawa T., Kasai T., Yabuki T.,
RA   Motoda Y., Harada T., Watanabe S., Inoue M., Hayashizaki Y., Tanaka A.,
RA   Kigawa T., Yokoyama S.;
RT   "Structure of the C-terminal phosphotyrosine interaction domain of Fe65L1
RT   complexed with the cytoplasmic tail of amyloid precursor protein reveals a
RT   novel peptide binding mode.";
RL   J. Biol. Chem. 283:27165-27178(2008).
CC   -!- FUNCTION: Functions as a cell surface receptor and performs
CC       physiological functions on the surface of neurons relevant to neurite
CC       growth, neuronal adhesion and axonogenesis. Interaction between APP
CC       molecules on neighboring cells promotes synaptogenesis. Involved in
CC       cell mobility and transcription regulation through protein-protein
CC       interactions. Can promote transcription activation through binding to
CC       APBB1-KAT5 and inhibit Notch signaling through interaction with Numb.
CC       Couples to apoptosis-inducing pathways such as those mediated by G(o)
CC       and JIP. Inhibits G(o)-alpha ATPase activity (By similarity). Acts as a
CC       kinesin I membrane receptor, mediating the axonal transport of beta-
CC       secretase and presenilin 1 (By similarity). By acting as a kinesin I
CC       membrane receptor, plays a role in axonal anterograde transport of
CC       cargo towards synapses in axons (By similarity). May be involved in
CC       copper homeostasis/oxidative stress through copper ion reduction. Can
CC       regulate neurite outgrowth through binding to components of the
CC       extracellular matrix such as heparin and collagen I and IV (By
CC       similarity). The splice isoforms that contain the BPTI domain possess
CC       protease inhibitor activity. Induces a AGER-dependent pathway that
CC       involves activation of p38 MAPK, resulting in internalization of
CC       amyloid-beta peptide and leading to mitochondrial dysfunction in
CC       cultured cortical neurons (By similarity). Provides Cu(2+) ions for
CC       GPC1 which are required for release of nitric oxide (NO) and subsequent
CC       degradation of the heparan sulfate chains on GPC1. {ECO:0000250,
CC       ECO:0000250|UniProtKB:P05067, ECO:0000269|PubMed:15677459}.
CC   -!- FUNCTION: Amyloid-beta peptides are lipophilic metal chelators with
CC       metal-reducing activity. Binds transient metals such as copper, zinc
CC       and iron. Rat and mouse amyloid-beta peptides bind only weakly
CC       transient metals and have little reducing activity due to substitutions
CC       of transient metal chelating residues. Amyloid-beta protein 42 may
CC       activate mononuclear phagocytes in the brain and elicit inflammatory
CC       responses. Promotes both tau aggregation and TPK II-mediated
CC       phosphorylation. Also binds GPC1 in lipid rafts (By similarity).
CC       {ECO:0000250}.
CC   -!- FUNCTION: The gamma-CTF peptides as well as the caspase-cleaved
CC       peptides, including C31, are potent enhancers of neuronal apoptosis.
CC       {ECO:0000269|PubMed:15677459}.
CC   -!- SUBUNIT: Binds, via its C-terminus, to the PID domain of several
CC       cytoplasmic proteins, including APBB family members, the APBA family,
CC       MAPK8IP1, SHC1, NUMB and DAB1. Binding to DAB1 inhibits its serine
CC       phosphorylation. Interacts (via NPXY motif) with DAB2 (via PID domain);
CC       the interaction is impaired by tyrosine phosphorylation of the NPXY
CC       motif. Also interacts with GPCR-like protein BPP, APPBP1, IB1, KNS2
CC       (via its TPR domains), APPBP2 (via BaSS) and DDB1 (By similarity). In
CC       vitro, it binds MAPT via the MT-binding domains (By similarity).
CC       Associates with microtubules in the presence of ATP and in a kinesin-
CC       dependent manner (By similarity). Interacts, through a C-terminal
CC       domain, with GNAO1 (By similarity). Amyloid-beta protein 42 binds
CC       CHRNA7 in hippocampal neurons (By similarity). Amyloid-beta associates
CC       with HADH2 (By similarity). Interacts with ANKS1B and AGER (By
CC       similarity). Interacts with CPEB1. Interacts with ITM2B. Interacts with
CC       ITM2C. Interacts with IDE. Can form homodimers; dimerization is
CC       enhanced in the presence of Cu(2+) ions. Can form homodimers; this is
CC       promoted by heparin binding (By similarity). Amyloid-beta protein 40
CC       interacts with S100A9 (By similarity). CTF-alpha product of APP
CC       interacts with GSAP (By similarity). Isoform APP695 interacts with
CC       SORL1 (via N-terminal ectodomain); this interaction retains APP in the
CC       trans-Golgi network and reduces processing into soluble APP-alpha and
CC       amyloid-beta peptides (PubMed:16174740, PubMed:16407538). The C99
CC       fragment also interacts with SORL1 (PubMed:16407538). Isoform APP751
CC       interacts with SORL1 (PubMed:16174740). Isoform APP770 interacts with
CC       SORL1 (PubMed:16174740). Interacts with PLD3 (By similarity). Interacts
CC       with VDAC1 (PubMed:25168729). Interacts with NSG1; could regulate APP
CC       processing (PubMed:21084623). Amyloid-beta protein 42 interacts with
CC       FPR2 (By similarity). Interacts with SYT7 (PubMed:30429473). Interacts
CC       (via transmembrane region) with PSEN1; the interaction is direct (By
CC       similarity). Interacts with LRRK2 (PubMed:28720718). Interacts (via
CC       cytoplasmic domain) with KIF5B (By similarity). Interacts (via C-
CC       terminus) with APBB2/FE65L1 (via C-terminus) (PubMed:18650440).
CC       Interacts (via intracellular domain) with APBB3 (By similarity).
CC       {ECO:0000250|UniProtKB:P05067, ECO:0000250|UniProtKB:P08592,
CC       ECO:0000269|PubMed:16174740, ECO:0000269|PubMed:16407538,
CC       ECO:0000269|PubMed:18650440, ECO:0000269|PubMed:21084623,
CC       ECO:0000269|PubMed:25168729, ECO:0000269|PubMed:28720718,
CC       ECO:0000269|PubMed:30429473}.
CC   -!- INTERACTION:
CC       P12023; P98084: Apba2; NbExp=2; IntAct=EBI-78814, EBI-81669;
CC       P12023; Q9QXJ1: Apbb1; NbExp=2; IntAct=EBI-78814, EBI-81338;
CC       P12023; Q03157: Aplp1; NbExp=4; IntAct=EBI-78814, EBI-399929;
CC       P12023; Q06335: Aplp2; NbExp=3; IntAct=EBI-78814, EBI-446708;
CC       P12023; P14211: Calr; NbExp=4; IntAct=EBI-78814, EBI-644340;
CC       P12023; P97318: Dab1; NbExp=3; IntAct=EBI-78814, EBI-81680;
CC       P12023; Q62108: Dlg4; NbExp=4; IntAct=EBI-78814, EBI-300895;
CC       P12023; Q8BGT1: Flrt3; NbExp=2; IntAct=EBI-78814, EBI-16166902;
CC       P12023; Q9D1T0: Lingo1; NbExp=2; IntAct=EBI-78814, EBI-2012981;
CC       P12023; Q9WVI9-1: Mapk8ip1; NbExp=3; IntAct=EBI-78814, EBI-288461;
CC       P12023; P27671: Rasgrf1; NbExp=2; IntAct=EBI-78814, EBI-645522;
CC       P12023; Q61120: Shc3; NbExp=2; IntAct=EBI-78814, EBI-79107;
CC       P12023; Q9JHI9: Slc40a1; NbExp=2; IntAct=EBI-78814, EBI-2931424;
CC       P12023; O88307: Sorl1; NbExp=3; IntAct=EBI-78814, EBI-7540114;
CC       P12023; Q6PHU5: Sort1; NbExp=3; IntAct=EBI-78814, EBI-6985663;
CC       P12023; A0A1I9GFB9; NbExp=2; IntAct=EBI-78814, EBI-21016230;
CC       P12023; P15253: CALR; Xeno; NbExp=2; IntAct=EBI-78814, EBI-9005200;
CC       P12023; Q9UQF2: MAPK8IP1; Xeno; NbExp=2; IntAct=EBI-78814, EBI-78404;
CC       P12023-2; Q9WVI9-1: Mapk8ip1; NbExp=2; IntAct=EBI-286828, EBI-288461;
CC       PRO_0000000118; P54763: Ephb2; NbExp=4; IntAct=EBI-14022231, EBI-537711;
CC       PRO_0000000118; P04925: Prnp; NbExp=2; IntAct=EBI-14022231, EBI-768613;
CC   -!- SUBCELLULAR LOCATION: Cell membrane {ECO:0000269|PubMed:26260791};
CC       Single-pass type I membrane protein {ECO:0000250|UniProtKB:P05067}.
CC       Membrane {ECO:0000250|UniProtKB:P05067}; Single-pass type I membrane
CC       protein {ECO:0000250|UniProtKB:P05067}. Perikaryon
CC       {ECO:0000250|UniProtKB:P08592}. Cell projection, growth cone
CC       {ECO:0000250|UniProtKB:P08592}. Membrane, clathrin-coated pit
CC       {ECO:0000250|UniProtKB:P05067}. Early endosome
CC       {ECO:0000269|PubMed:25592972, ECO:0000269|PubMed:26260791}. Cytoplasmic
CC       vesicle {ECO:0000250|UniProtKB:P05067}. Golgi apparatus, trans-Golgi
CC       network {ECO:0000269|PubMed:23931995}. Note=Cell surface protein that
CC       rapidly becomes internalized via clathrin-coated pits. Only a minor
CC       proportion is present at the cell membrane; most of the protein is
CC       present in intracellular vesicles. During maturation, the immature APP
CC       (N-glycosylated in the endoplasmic reticulum) moves to the Golgi
CC       complex where complete maturation occurs (O-glycosylated and sulfated).
CC       After alpha-secretase cleavage, soluble APP is released into the
CC       extracellular space and the C-terminal is internalized to endosomes and
CC       lysosomes. Some APP accumulates in secretory transport vesicles leaving
CC       the late Golgi compartment and returns to the cell surface. APP sorts
CC       to the basolateral surface in epithelial cells. During neuronal
CC       differentiation, the Thr-743 phosphorylated form is located mainly in
CC       growth cones, moderately in neurites and sparingly in the cell body.
CC       Casein kinase phosphorylation can occur either at the cell surface or
CC       within a post-Golgi compartment (By similarity). Associates with GPC1
CC       in perinuclear compartments (PubMed:15677459). Colocalizes with SORL1
CC       in a vesicular pattern in cytoplasm and perinuclear regions (By
CC       similarity). Upon neuronal activation, routed into BACE1-positive
CC       recycling endosomes via a clathrin -dependent mechanism
CC       (PubMed:23931995). {ECO:0000250|UniProtKB:P05067,
CC       ECO:0000269|PubMed:15677459, ECO:0000269|PubMed:23931995}.
CC   -!- SUBCELLULAR LOCATION: [C99]: Early endosome
CC       {ECO:0000250|UniProtKB:P05067}.
CC   -!- SUBCELLULAR LOCATION: [C83]: Endoplasmic reticulum
CC       {ECO:0000250|UniProtKB:P05067}. Golgi apparatus
CC       {ECO:0000250|UniProtKB:P05067}. Early endosome
CC       {ECO:0000250|UniProtKB:P05067}.
CC   -!- SUBCELLULAR LOCATION: [Soluble APP-beta]: Secreted {ECO:0000305}.
CC   -!- SUBCELLULAR LOCATION: [Amyloid-beta protein 42]: Cell surface.
CC       Note=Associates with FPR2 at the cell surface and the complex is then
CC       rapidly internalized. {ECO:0000250|UniProtKB:P05067}.
CC   -!- SUBCELLULAR LOCATION: [Gamma-secretase C-terminal fragment 59]: Nucleus
CC       {ECO:0000269|PubMed:28720718}. Cytoplasm
CC       {ECO:0000250|UniProtKB:P05067}. Note=Located to both the cytoplasm and
CC       nuclei of neurons. It can be translocated to the nucleus through
CC       association with APBB1 (Fe65) (By similarity). In dopaminergic neurons,
CC       the phosphorylated Thr-743 form is localized to the nucleus
CC       (PubMed:28720718). {ECO:0000250|UniProtKB:P05067,
CC       ECO:0000269|PubMed:28720718}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=4;
CC         Comment=Additional isoforms seem to exist.;
CC       Name=APP770;
CC         IsoId=P12023-1; Sequence=Displayed;
CC       Name=APP695;
CC         IsoId=P12023-2; Sequence=VSP_000012, VSP_000013;
CC       Name=APP751;
CC         IsoId=P12023-3; Sequence=VSP_000014;
CC       Name=APP714;
CC         IsoId=P12023-4; Sequence=Not described;
CC   -!- TISSUE SPECIFICITY: Expressed in the brain with expression in cortex,
CC       cerebellum, hippocampus, olfactory bulb, neurons, astrocytes and
CC       microglia (at protein level) (PubMed:25757569, PubMed:26260791,
CC       PubMed:28720718). Expressed in the retinal lens (PubMed:25757569).
CC       Expressed at a low level in muscle cells (at protein level)
CC       (PubMed:25757569). {ECO:0000269|PubMed:25757569,
CC       ECO:0000269|PubMed:26260791, ECO:0000269|PubMed:28720718}.
CC   -!- TISSUE SPECIFICITY: [Isoform APP770]: Expressed in kidney.
CC       {ECO:0000269|PubMed:8510506}.
CC   -!- TISSUE SPECIFICITY: [Isoform APP751]: Widely expressed
CC       (PubMed:8510506). Expressed in several different brain regions
CC       including hippocampus, substantia nigra pars compacta and cerebellum
CC       (PubMed:8510506). Within the cerebellum, abundantly expressed in
CC       Purkinje cells (PubMed:8510506). {ECO:0000269|PubMed:8510506}.
CC   -!- TISSUE SPECIFICITY: [Isoform APP695]: Expressed in the brain, kidney
CC       and liver (PubMed:8510506). Expressed in several different brain
CC       regions including hippocampus, substantia nigra pars compacta and
CC       cerebellum (PubMed:8510506). Within the cerebellum, abundantly
CC       expressed in Purkinje cells (PubMed:8510506).
CC       {ECO:0000269|PubMed:8510506}.
CC   -!- TISSUE SPECIFICITY: [Isoform APP714]: Expressed in several different
CC       brain regions including hippocampus, substantia nigra pars compacta and
CC       cerebellum (PubMed:8510506). Within the cerebellum, abundantly
CC       expressed in Purkinje cells (PubMed:8510506).
CC       {ECO:0000269|PubMed:8510506}.
CC   -!- DEVELOPMENTAL STAGE: Expressed in 4 to 24 week old mice.
CC       {ECO:0000269|PubMed:26260791}.
CC   -!- INDUCTION: Up-regulated in animals on a high-fat diet compared to a
CC       regular diet. {ECO:0000269|PubMed:26260791}.
CC   -!- DOMAIN: The transmembrane helix undergoes a conformation change and
CC       unravels partially when bound to PSEN1, facilitating cleavage by PSEN1.
CC       {ECO:0000250|UniProtKB:P05067}.
CC   -!- DOMAIN: The basolateral sorting signal (BaSS) is required for sorting
CC       of membrane proteins to the basolateral surface of epithelial cells.
CC       {ECO:0000250|UniProtKB:P05067}.
CC   -!- DOMAIN: The GFLD subdomain binds Cu(2+) ions; this promotes
CC       homodimerization. {ECO:0000250|UniProtKB:P05067}.
CC   -!- DOMAIN: The NPXY sequence motif found in many tyrosine-phosphorylated
CC       proteins is required for the specific binding of the PID domain.
CC       However, additional amino acids either N- or C-terminal to the NPXY
CC       motif are often required for complete interaction. The PID domain-
CC       containing proteins which bind APP require the YENPTY motif for full
CC       interaction. These interactions are independent of phosphorylation on
CC       the terminal tyrosine residue. The YENPXY site is also involved in
CC       clathrin-mediated endocytosis. {ECO:0000250|UniProtKB:P05067}.
CC   -!- DOMAIN: The C-terminal region can bind zinc ions; this favors
CC       dimerization and formation of higher oligomers.
CC       {ECO:0000250|UniProtKB:P05067}.
CC   -!- DOMAIN: The OX-2 motif shows some similarity to a region in the N-
CC       terminus of CD200/MOX2. {ECO:0000250|UniProtKB:P05067}.
CC   -!- PTM: Proteolytically processed under normal cellular conditions
CC       (PubMed:11553691, PubMed:23931995). Cleavage either by alpha-secretase,
CC       beta-secretase or theta-secretase leads to generation and extracellular
CC       release of soluble APP peptides, S-APP-alpha and S-APP-beta, and the
CC       retention of corresponding membrane-anchored C-terminal fragments, C80,
CC       C83 and C99 (PubMed:11553691, PubMed:23931995). Subsequent processing
CC       of C80 and C83 by gamma-secretase yields P3 peptides. This is the major
CC       secretory pathway and is non-amyloidogenic. Alternatively,
CC       presenilin/nicastrin-mediated gamma-secretase processing of C99
CC       releases the amyloid-beta proteins, amyloid-beta protein 40 and
CC       amyloid-beta protein 42, major components of amyloid plaques, and the
CC       cytotoxic C-terminal fragments, gamma-CTF(50), gamma-CTF(57) and gamma-
CC       CTF(59). PSEN1 cleavage is more efficient with C83 than with C99 as
CC       substrate (in vitro). Amyloid-beta protein 40 and Amyloid-beta protein
CC       42 are cleaved by ACE. Many other minor amyloid-beta peptides, amyloid-
CC       beta 1-X peptides, are found in cerebral spinal fluid (CSF) including
CC       the amyloid-beta X-15 peptides, produced from the cleavage by alpha-
CC       secretase (By similarity). {ECO:0000250|UniProtKB:P05067,
CC       ECO:0000269|PubMed:11553691, ECO:0000269|PubMed:23931995}.
CC   -!- PTM: Proteolytically cleaved by caspases during neuronal apoptosis.
CC       Cleavage at Asp-739 by either CASP6, CASP8 or CASP9 results in the
CC       production of the neurotoxic C31 peptide and the increased production
CC       of amyloid-beta peptides. {ECO:0000250|UniProtKB:P05067}.
CC   -!- PTM: N- and O-glycosylated. {ECO:0000250|UniProtKB:P05067}.
CC   -!- PTM: Phosphorylation in the C-terminal on tyrosine, threonine and
CC       serine residues is neuron-specific (By similarity). Phosphorylation can
CC       affect APP processing, neuronal differentiation and interaction with
CC       other proteins (By similarity). Phosphorylated on Thr-743 in neuronal
CC       cells by Cdc5 kinase and Mapk10, in dividing cells by Cdc2 kinase in a
CC       cell-cycle dependent manner with maximal levels at the G2/M phase and,
CC       in vitro, by GSK-3-beta (By similarity). The Thr-743 phosphorylated
CC       form causes a conformational change which reduces binding of Fe65
CC       family members (By similarity). In dopaminergic (DA) neurons,
CC       phosphorylation on Thr-743 by LRKK2 promotes the production and the
CC       nuclear translocation of the APP intracellular domain (AICD) which
CC       induces DA neuron apoptosis (PubMed:28720718). Phosphorylation on Tyr-
CC       757 is required for SHC binding (By similarity). Phosphorylated in the
CC       extracellular domain by casein kinases on both soluble and membrane-
CC       bound APP (By similarity). This phosphorylation is inhibited by heparin
CC       (By similarity). {ECO:0000250|UniProtKB:P05067,
CC       ECO:0000269|PubMed:28720718}.
CC   -!- PTM: Extracellular binding and reduction of copper, results in a
CC       corresponding oxidation of Cys-144 and Cys-158, and the formation of a
CC       disulfide bond. {ECO:0000250}.
CC   -!- PTM: Trophic-factor deprivation triggers the cleavage of surface APP by
CC       beta-secretase to release sAPP-beta which is further cleaved to release
CC       an N-terminal fragment of APP (N-APP). {ECO:0000250}.
CC   -!- PTM: Amyloid-beta peptides are degraded by IDE.
CC       {ECO:0000269|PubMed:12634421}.
CC   -!- PTM: Sulfated on tyrosine residues. {ECO:0000250|UniProtKB:P05067}.
CC   -!- MISCELLANEOUS: Chelation of metal ions, notably copper, iron and zinc,
CC       can induce histidine-bridging between amyloid-beta molecules resulting
CC       in amyloid-beta-metal aggregates. Rat and mouse amyloid-beta peptides
CC       have an arginine residue substituted for the bridging histidine residue
CC       and are thus less capable of forming amyloid aggregates. Extracellular
CC       zinc-binding increases binding of heparin to APP and inhibits collagen-
CC       binding (By similarity). {ECO:0000250|UniProtKB:P05067, ECO:0000305}.
CC   -!- SIMILARITY: Belongs to the APP family. {ECO:0000255|PROSITE-
CC       ProRule:PRU01217}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; M18373; AAA37139.1; -; mRNA.
DR   EMBL; X59379; -; NOT_ANNOTATED_CDS; mRNA.
DR   EMBL; U84012; AAB41502.1; -; mRNA.
DR   EMBL; D10603; BAA01456.1; -; Genomic_DNA.
DR   EMBL; BC005490; AAH05490.1; -; mRNA.
DR   EMBL; M24397; AAA39929.1; -; mRNA.
DR   EMBL; X15210; CAA33280.1; -; mRNA.
DR   EMBL; U82624; AAB40919.1; -; Genomic_DNA.
DR   CCDS; CCDS28285.1; -. [P12023-2]
DR   CCDS; CCDS88958.1; -. [P12023-1]
DR   PIR; A27485; A27485.
DR   PIR; A32282; A32282.
DR   PIR; S04855; S04855.
DR   RefSeq; NP_001185752.1; NM_001198823.1. [P12023-1]
DR   PDB; 2ROZ; NMR; -; A=739-770.
DR   PDB; 2YSZ; NMR; -; A=739-770.
DR   PDB; 2YT0; NMR; -; A=739-770.
DR   PDB; 2YT1; NMR; -; A=739-770.
DR   PDB; 4YN0; X-ray; 2.20 A; B=370-592.
DR   PDB; 5MYK; X-ray; 1.60 A; C=674-689.
DR   PDB; 7MRN; X-ray; 3.50 A; C/D=19-190.
DR   PDB; 8BG9; EM; 3.50 A; A/B=672-708.
DR   PDB; 8S4Y; X-ray; 2.70 A; A=754-764.
DR   PDBsum; 2ROZ; -.
DR   PDBsum; 2YSZ; -.
DR   PDBsum; 2YT0; -.
DR   PDBsum; 2YT1; -.
DR   PDBsum; 4YN0; -.
DR   PDBsum; 5MYK; -.
DR   PDBsum; 7MRN; -.
DR   PDBsum; 8BG9; -.
DR   PDBsum; 8S4Y; -.
DR   AlphaFoldDB; P12023; -.
DR   BMRB; P12023; -.
DR   EMDB; EMD-16027; -.
DR   SMR; P12023; -.
DR   BioGRID; 198167; 178.
DR   ComplexPortal; CPX-1105; Amyloid-beta protein 40/42 complex.
DR   ComplexPortal; CPX-1106; Amyloid-beta protein 40 complex.
DR   ComplexPortal; CPX-1107; Amyloid-beta protein 42 complex.
DR   ComplexPortal; CPX-1121; Amyloid-beta protein 40/42 oligomeric complex.
DR   ComplexPortal; CPX-1139; Amyloid-beta protein 42 oligomeric complex.
DR   ComplexPortal; CPX-1181; Amyloid-beta protein 40 oligomeric complex.
DR   CORUM; P12023; -.
DR   ELM; P12023; -.
DR   FunCoup; P12023; 1315.
DR   IntAct; P12023; 85.
DR   MINT; P12023; -.
DR   STRING; 10090.ENSMUSP00000005406; -.
DR   ChEMBL; CHEMBL4523942; -.
DR   MEROPS; I02.015; -.
DR   GlyCosmos; P12023; 2 sites, No reported glycans.
DR   GlyGen; P12023; 5 sites, 1 N-linked glycan (1 site), 1 O-linked glycan (3 sites).
DR   iPTMnet; P12023; -.
DR   PhosphoSitePlus; P12023; -.
DR   SwissPalm; P12023; -.
DR   jPOST; P12023; -.
DR   PeptideAtlas; P12023; -.
DR   ProteomicsDB; 285696; -. [P12023-1]
DR   ProteomicsDB; 285697; -. [P12023-2]
DR   ProteomicsDB; 285698; -. [P12023-3]
DR   Pumba; P12023; -.
DR   ABCD; P12023; 5 sequenced antibodies.
DR   Antibodypedia; 668; 4415 antibodies from 54 providers.
DR   DNASU; 11820; -.
DR   Ensembl; ENSMUST00000005406.12; ENSMUSP00000005406.11; ENSMUSG00000022892.12. [P12023-2]
DR   Ensembl; ENSMUST00000227723.2; ENSMUSP00000154061.2; ENSMUSG00000022892.12. [P12023-1]
DR   GeneID; 11820; -.
DR   KEGG; mmu:11820; -.
DR   UCSC; uc007ztn.2; mouse. [P12023-1]
DR   AGR; MGI:88059; -.
DR   CTD; 351; -.
DR   MGI; MGI:88059; App.
DR   VEuPathDB; HostDB:ENSMUSG00000022892; -.
DR   eggNOG; KOG3540; Eukaryota.
DR   GeneTree; ENSGT00530000063252; -.
DR   HOGENOM; CLU_014607_2_1_1; -.
DR   InParanoid; P12023; -.
DR   OMA; ANWTNEH; -.
DR   OrthoDB; 6147836at2759; -.
DR   PhylomeDB; P12023; -.
DR   Reactome; R-MMU-114608; Platelet degranulation.
DR   Reactome; R-MMU-3000178; ECM proteoglycans.
DR   Reactome; R-MMU-381426; Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs).
DR   Reactome; R-MMU-416476; G alpha (q) signalling events.
DR   Reactome; R-MMU-418594; G alpha (i) signalling events.
DR   Reactome; R-MMU-432720; Lysosome Vesicle Biogenesis.
DR   Reactome; R-MMU-444473; Formyl peptide receptors bind formyl peptides and many other ligands.
DR   Reactome; R-MMU-445989; TAK1-dependent IKK and NF-kappa-B activation.
DR   Reactome; R-MMU-879415; Advanced glycosylation endproduct receptor signaling.
DR   Reactome; R-MMU-8957275; Post-translational protein phosphorylation.
DR   Reactome; R-MMU-933542; TRAF6 mediated NF-kB activation.
DR   Reactome; R-MMU-9609523; Insertion of tail-anchored proteins into the endoplasmic reticulum membrane.
DR   Reactome; R-MMU-9837999; Mitochondrial protein degradation.
DR   BioGRID-ORCS; 11820; 1 hit in 77 CRISPR screens.
DR   CD-CODE; 01CA17F3; Centrosome.
DR   ChiTaRS; App; mouse.
DR   EvolutionaryTrace; P12023; -.
DR   PRO; PR:P12023; -.
DR   Proteomes; UP000000589; Chromosome 16.
DR   RNAct; P12023; protein.
DR   Bgee; ENSMUSG00000022892; Expressed in ciliary body and 287 other cell types or tissues.
DR   ExpressionAtlas; P12023; baseline and differential.
DR   GO; GO:0045177; C:apical part of cell; IDA:MGI.
DR   GO; GO:0030424; C:axon; IDA:UniProtKB.
DR   GO; GO:0009986; C:cell surface; IDA:MGI.
DR   GO; GO:0005911; C:cell-cell junction; IDA:MGI.
DR   GO; GO:0035253; C:ciliary rootlet; IDA:MGI.
DR   GO; GO:0005905; C:clathrin-coated pit; IEA:UniProtKB-SubCell.
DR   GO; GO:0030134; C:COPII-coated ER to Golgi transport vesicle; IDA:MGI.
DR   GO; GO:0005737; C:cytoplasm; IDA:MGI.
DR   GO; GO:0031410; C:cytoplasmic vesicle; IDA:MGI.
DR   GO; GO:0005769; C:early endosome; IDA:MGI.
DR   GO; GO:0005783; C:endoplasmic reticulum; ISS:UniProtKB.
DR   GO; GO:0005576; C:extracellular region; IEA:UniProtKB-SubCell.
DR   GO; GO:0005794; C:Golgi apparatus; IDA:MGI.
DR   GO; GO:0005798; C:Golgi-associated vesicle; IDA:UniProtKB.
DR   GO; GO:0030426; C:growth cone; IEA:UniProtKB-SubCell.
DR   GO; GO:0097708; C:intracellular vesicle; IDA:MGI.
DR   GO; GO:0016020; C:membrane; IDA:MGI.
DR   GO; GO:0031594; C:neuromuscular junction; IDA:MGI.
DR   GO; GO:0043005; C:neuron projection; IDA:MGI.
DR   GO; GO:0005634; C:nucleus; IEA:UniProtKB-SubCell.
DR   GO; GO:0043204; C:perikaryon; IEA:UniProtKB-SubCell.
DR   GO; GO:0048471; C:perinuclear region of cytoplasm; IDA:MGI.
DR   GO; GO:0005886; C:plasma membrane; IDA:MGI.
DR   GO; GO:0048786; C:presynaptic active zone; IDA:SynGO.
DR   GO; GO:0043235; C:receptor complex; ISO:MGI.
DR   GO; GO:0055037; C:recycling endosome; IDA:UniProtKB.
DR   GO; GO:0005790; C:smooth endoplasmic reticulum; IEA:GOC.
DR   GO; GO:0051233; C:spindle midzone; IDA:MGI.
DR   GO; GO:0008021; C:synaptic vesicle; IDA:MGI.
DR   GO; GO:0008201; F:heparin binding; IEA:UniProtKB-KW.
DR   GO; GO:0042802; F:identical protein binding; ISO:MGI.
DR   GO; GO:0019904; F:protein domain specific binding; IDA:MGI.
DR   GO; GO:0019901; F:protein kinase binding; IPI:ARUK-UCL.
DR   GO; GO:0000978; F:RNA polymerase II cis-regulatory region sequence-specific DNA binding; IDA:MGI.
DR   GO; GO:0004867; F:serine-type endopeptidase inhibitor activity; IEA:UniProtKB-KW.
DR   GO; GO:0030546; F:signaling receptor activator activity; IDA:ARUK-UCL.
DR   GO; GO:0046914; F:transition metal ion binding; IEA:InterPro.
DR   GO; GO:0008344; P:adult locomotory behavior; IMP:MGI.
DR   GO; GO:0008088; P:axo-dendritic transport; IMP:MGI.
DR   GO; GO:0016199; P:axon midline choice point recognition; IMP:MGI.
DR   GO; GO:0007409; P:axonogenesis; IMP:MGI.
DR   GO; GO:0007155; P:cell adhesion; IEA:UniProtKB-KW.
DR   GO; GO:0021953; P:central nervous system neuron differentiation; IGI:MGI.
DR   GO; GO:0008203; P:cholesterol metabolic process; IMP:MGI.
DR   GO; GO:0050890; P:cognition; IDA:MGI.
DR   GO; GO:0048669; P:collateral sprouting in absence of injury; IGI:MGI.
DR   GO; GO:0180011; P:cytosolic mRNA polyadenylation; IDA:MGI.
DR   GO; GO:0016358; P:dendrite development; IMP:MGI.
DR   GO; GO:0006897; P:endocytosis; IMP:MGI.
DR   GO; GO:0030198; P:extracellular matrix organization; IGI:MGI.
DR   GO; GO:0030900; P:forebrain development; IMP:MGI.
DR   GO; GO:0000086; P:G2/M transition of mitotic cell cycle; IMP:MGI.
DR   GO; GO:0010467; P:gene expression; IMP:MGI.
DR   GO; GO:0006878; P:intracellular copper ion homeostasis; IMP:MGI.
DR   GO; GO:0035235; P:ionotropic glutamate receptor signaling pathway; IMP:MGI.
DR   GO; GO:0007626; P:locomotory behavior; IGI:MGI.
DR   GO; GO:0060291; P:long-term synaptic potentiation; TAS:ARUK-UCL.
DR   GO; GO:0007617; P:mating behavior; IGI:MGI.
DR   GO; GO:0007613; P:memory; TAS:ARUK-UCL.
DR   GO; GO:0000278; P:mitotic cell cycle; IMP:MGI.
DR   GO; GO:0045665; P:negative regulation of neuron differentiation; IDA:MGI.
DR   GO; GO:1905607; P:negative regulation of presynapse assembly; IMP:MGI.
DR   GO; GO:0050885; P:neuromuscular process controlling balance; IGI:MGI.
DR   GO; GO:0051402; P:neuron apoptotic process; IGI:MGI.
DR   GO; GO:0070050; P:neuron cellular homeostasis; IGI:MGI.
DR   GO; GO:0030182; P:neuron differentiation; IDA:MGI.
DR   GO; GO:0031175; P:neuron projection development; IDA:MGI.
DR   GO; GO:0016322; P:neuron remodeling; IMP:MGI.
DR   GO; GO:0007219; P:Notch signaling pathway; IEA:UniProtKB-KW.
DR   GO; GO:0010971; P:positive regulation of G2/M transition of mitotic cell cycle; IMP:MGI.
DR   GO; GO:0045931; P:positive regulation of mitotic cell cycle; IMP:MGI.
DR   GO; GO:0045944; P:positive regulation of transcription by RNA polymerase II; IDA:MGI.
DR   GO; GO:0010468; P:regulation of gene expression; IDA:MGI.
DR   GO; GO:0040014; P:regulation of multicellular organism growth; IMP:MGI.
DR   GO; GO:0050803; P:regulation of synapse structure or activity; IMP:MGI.
DR   GO; GO:0006417; P:regulation of translation; IDA:MGI.
DR   GO; GO:0006979; P:response to oxidative stress; IGI:MGI.
DR   GO; GO:0051563; P:smooth endoplasmic reticulum calcium ion homeostasis; IGI:MGI.
DR   GO; GO:0001967; P:suckling behavior; IGI:MGI.
DR   GO; GO:0051124; P:synaptic assembly at neuromuscular junction; IGI:MGI.
DR   GO; GO:0008542; P:visual learning; IMP:MGI.
DR   CDD; cd22607; Kunitz_ABPP-like; 1.
DR   FunFam; 3.30.1490.140:FF:000001; Amyloid beta (A4) protein b; 1.
DR   FunFam; 3.90.570.10:FF:000001; Amyloid beta A4 protein; 1.
DR   FunFam; 4.10.410.10:FF:000001; Amyloid beta A4 protein; 1.
DR   FunFam; 1.20.120.770:FF:000001; Amyloid beta A4 protein-like isoform 1; 1.
DR   Gene3D; 6.10.250.1670; -; 1.
DR   Gene3D; 1.20.120.770; Amyloid precursor protein, E2 domain; 1.
DR   Gene3D; 3.30.1490.140; Amyloidogenic glycoprotein, copper-binding domain; 1.
DR   Gene3D; 3.90.570.10; Amyloidogenic glycoprotein, heparin-binding domain; 1.
DR   Gene3D; 4.10.410.10; Pancreatic trypsin inhibitor Kunitz domain; 1.
DR   Gene3D; 2.30.29.30; Pleckstrin-homology domain (PH domain)/Phosphotyrosine-binding domain (PTB); 1.
DR   InterPro; IPR036669; Amyloid_Cu-bd_sf.
DR   InterPro; IPR008155; Amyloid_glyco.
DR   InterPro; IPR013803; Amyloid_glyco_Abeta.
DR   InterPro; IPR011178; Amyloid_glyco_Cu-bd.
DR   InterPro; IPR024329; Amyloid_glyco_E2_domain.
DR   InterPro; IPR008154; Amyloid_glyco_extra.
DR   InterPro; IPR015849; Amyloid_glyco_heparin-bd.
DR   InterPro; IPR036454; Amyloid_glyco_heparin-bd_sf.
DR   InterPro; IPR019745; Amyloid_glyco_intracell_CS.
DR   InterPro; IPR019543; APP_amyloid_C.
DR   InterPro; IPR019744; APP_CUBD_CS.
DR   InterPro; IPR036176; E2_sf.
DR   InterPro; IPR002223; Kunitz_BPTI.
DR   InterPro; IPR036880; Kunitz_BPTI_sf.
DR   InterPro; IPR011993; PH-like_dom_sf.
DR   InterPro; IPR020901; Prtase_inh_Kunz-CS.
DR   PANTHER; PTHR23103; ALZHEIMER'S DISEASE BETA-AMYLOID RELATED; 1.
DR   PANTHER; PTHR23103:SF7; AMYLOID-BETA PRECURSOR PROTEIN; 1.
DR   Pfam; PF10515; APP_amyloid; 1.
DR   Pfam; PF12924; APP_Cu_bd; 1.
DR   Pfam; PF12925; APP_E2; 1.
DR   Pfam; PF02177; APP_N; 1.
DR   Pfam; PF03494; Beta-APP; 1.
DR   Pfam; PF00014; Kunitz_BPTI; 1.
DR   PRINTS; PR00203; AMYLOIDA4.
DR   PRINTS; PR00759; BASICPTASE.
DR   PRINTS; PR00204; BETAAMYLOID.
DR   SMART; SM00006; A4_EXTRA; 1.
DR   SMART; SM00131; KU; 1.
DR   SUPFAM; SSF56491; A heparin-binding domain; 1.
DR   SUPFAM; SSF89811; Amyloid beta a4 protein copper binding domain (domain 2); 1.
DR   SUPFAM; SSF57362; BPTI-like; 1.
DR   SUPFAM; SSF109843; CAPPD, an extracellular domain of amyloid beta A4 protein; 1.
DR   PROSITE; PS00319; APP_CUBD; 1.
DR   PROSITE; PS51869; APP_E1; 1.
DR   PROSITE; PS51870; APP_E2; 1.
DR   PROSITE; PS00320; APP_INTRA; 1.
DR   PROSITE; PS00280; BPTI_KUNITZ_1; 1.
DR   PROSITE; PS50279; BPTI_KUNITZ_2; 1.
DR   TreeFam; TF317274; -.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative splicing; Amyloid; Apoptosis; Cell adhesion;
KW   Cell membrane; Cell projection; Coated pit; Copper; Cytoplasm;
KW   Cytoplasmic vesicle; Disulfide bond; Endocytosis; Endoplasmic reticulum;
KW   Endosome; Glycoprotein; Golgi apparatus; Heparin-binding; Iron;
KW   Isopeptide bond; Membrane; Metal-binding; Notch signaling pathway; Nucleus;
KW   Phosphoprotein; Protease inhibitor; Reference proteome; Secreted;
KW   Serine protease inhibitor; Signal; Sulfation; Transmembrane;
KW   Transmembrane helix; Ubl conjugation; Zinc.
FT   SIGNAL          1..17
FT                   /evidence="ECO:0000250|UniProtKB:P05067"
FT   CHAIN           18..770
FT                   /note="Amyloid-beta precursor protein"
FT                   /id="PRO_0000000114"
FT   CHAIN           18..687
FT                   /note="Soluble APP-alpha"
FT                   /evidence="ECO:0000255"
FT                   /id="PRO_0000000115"
FT   CHAIN           18..671
FT                   /note="Soluble APP-beta"
FT                   /evidence="ECO:0000255"
FT                   /id="PRO_0000000116"
FT   CHAIN           18..286
FT                   /note="N-APP"
FT                   /evidence="ECO:0000250"
FT                   /id="PRO_0000381968"
FT   CHAIN           672..770
FT                   /note="C99"
FT                   /evidence="ECO:0000250"
FT                   /id="PRO_0000000117"
FT   CHAIN           672..713
FT                   /note="Amyloid-beta protein 42"
FT                   /evidence="ECO:0000250|UniProtKB:P05067"
FT                   /id="PRO_0000000118"
FT   CHAIN           672..711
FT                   /note="Amyloid-beta protein 40"
FT                   /evidence="ECO:0000250|UniProtKB:P05067"
FT                   /id="PRO_0000000119"
FT   CHAIN           688..770
FT                   /note="C83"
FT                   /evidence="ECO:0000250"
FT                   /id="PRO_0000000120"
FT   PEPTIDE         688..713
FT                   /note="P3(42)"
FT                   /evidence="ECO:0000250"
FT                   /id="PRO_0000000121"
FT   PEPTIDE         688..711
FT                   /note="P3(40)"
FT                   /evidence="ECO:0000250"
FT                   /id="PRO_0000000122"
FT   CHAIN           691..770
FT                   /note="C80"
FT                   /id="PRO_0000384576"
FT   CHAIN           712..770
FT                   /note="Gamma-secretase C-terminal fragment 59"
FT                   /id="PRO_0000000123"
FT   CHAIN           714..770
FT                   /note="Gamma-secretase C-terminal fragment 57"
FT                   /id="PRO_0000000124"
FT   CHAIN           721..770
FT                   /note="Gamma-secretase C-terminal fragment 50"
FT                   /id="PRO_0000000125"
FT   CHAIN           740..770
FT                   /note="C31"
FT                   /evidence="ECO:0000250"
FT                   /id="PRO_0000000126"
FT   TOPO_DOM        18..701
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000305"
FT   TRANSMEM        702..722
FT                   /note="Helical"
FT                   /evidence="ECO:0000250|UniProtKB:P05067"
FT   TOPO_DOM        723..770
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000305"
FT   DOMAIN          28..189
FT                   /note="E1"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU01217"
FT   DOMAIN          291..341
FT                   /note="BPTI/Kunitz inhibitor"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00031"
FT   DOMAIN          374..565
FT                   /note="E2"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU01218"
FT   REGION          28..123
FT                   /note="GFLD subdomain"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU01217"
FT   REGION          131..189
FT                   /note="CuBD subdomain"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU01217"
FT   REGION          181..188
FT                   /note="Zinc-binding"
FT                   /evidence="ECO:0000250"
FT   REGION          193..284
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          391..423
FT                   /note="Heparin-binding"
FT                   /evidence="ECO:0000250"
FT   REGION          491..522
FT                   /note="Heparin-binding"
FT                   /evidence="ECO:0000250"
FT   REGION          523..540
FT                   /note="Collagen-binding"
FT                   /evidence="ECO:0000250|UniProtKB:P05067"
FT   REGION          695..722
FT                   /note="Interaction with PSEN1"
FT                   /evidence="ECO:0000250|UniProtKB:P05067"
FT   REGION          732..751
FT                   /note="Interaction with G(o)-alpha"
FT                   /evidence="ECO:0000250"
FT   REGION          756..770
FT                   /note="Interaction with DAB2"
FT                   /evidence="ECO:0000269|PubMed:11247302"
FT   REGION          756..770
FT                   /note="Required for the interaction with KIF5B and for
FT                   anterograde transport in axons"
FT                   /evidence="ECO:0000250|UniProtKB:P05067"
FT   MOTIF           344..365
FT                   /note="OX-2"
FT                   /evidence="ECO:0000250|UniProtKB:P05067"
FT   MOTIF           724..734
FT                   /note="Basolateral sorting signal"
FT   MOTIF           757..762
FT                   /note="YENPXY motif; contains endocytosis signal"
FT                   /evidence="ECO:0000250|UniProtKB:P05067"
FT   COMPBIAS        193..207
FT                   /note="Acidic residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        228..264
FT                   /note="Acidic residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        268..281
FT                   /note="Low complexity"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   BINDING         96..110
FT                   /ligand="heparin"
FT                   /ligand_id="ChEBI:CHEBI:28304"
FT                   /evidence="ECO:0000250|UniProtKB:P05067"
FT   BINDING         147
FT                   /ligand="Cu(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29036"
FT                   /ligand_label="1"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU01217"
FT   BINDING         151
FT                   /ligand="Cu(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29036"
FT                   /ligand_label="1"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU01217"
FT   BINDING         168
FT                   /ligand="Cu(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29036"
FT                   /ligand_label="1"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU01217"
FT   BINDING         183
FT                   /ligand="Zn(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29105"
FT                   /ligand_label="1"
FT                   /evidence="ECO:0000250|UniProtKB:P05067"
FT   BINDING         186
FT                   /ligand="Zn(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29105"
FT                   /ligand_label="1"
FT                   /evidence="ECO:0000250|UniProtKB:P05067"
FT   BINDING         187
FT                   /ligand="Zn(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29105"
FT                   /ligand_label="1"
FT                   /evidence="ECO:0000250|UniProtKB:P05067"
FT   BINDING         677
FT                   /ligand="Cu(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29036"
FT                   /ligand_label="2"
FT                   /evidence="ECO:0000250|UniProtKB:P05067"
FT   BINDING         677
FT                   /ligand="Zn(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29105"
FT                   /ligand_label="2"
FT                   /evidence="ECO:0000250|UniProtKB:P05067"
FT   BINDING         685
FT                   /ligand="Cu(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29036"
FT                   /ligand_label="2"
FT                   /evidence="ECO:0000250|UniProtKB:P05067"
FT   BINDING         685
FT                   /ligand="Zn(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29105"
FT                   /ligand_label="2"
FT                   /evidence="ECO:0000250|UniProtKB:P05067"
FT   SITE            170
FT                   /note="Required for Cu(2+) reduction"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU01217"
FT   SITE            197..198
FT                   /note="Cleavage; by caspases"
FT                   /evidence="ECO:0000250|UniProtKB:P05067"
FT   SITE            219..220
FT                   /note="Cleavage; by caspases"
FT                   /evidence="ECO:0000250|UniProtKB:P05067"
FT   SITE            301..302
FT                   /note="Reactive bond"
FT                   /evidence="ECO:0000250"
FT   SITE            671..672
FT                   /note="Cleavage; by beta-secretase"
FT                   /evidence="ECO:0000250|UniProtKB:P05067"
FT   SITE            678..679
FT                   /note="Cleavage; by ACE"
FT                   /evidence="ECO:0000250|UniProtKB:P05067"
FT   SITE            687..688
FT                   /note="Cleavage; by alpha-secretase"
FT                   /evidence="ECO:0000250|UniProtKB:P08592"
FT   SITE            690..691
FT                   /note="Cleavage; by theta-secretase"
FT                   /evidence="ECO:0000250|UniProtKB:P08592"
FT   SITE            704
FT                   /note="Implicated in free radical propagation"
FT                   /evidence="ECO:0000250"
FT   SITE            706
FT                   /note="Susceptible to oxidation"
FT                   /evidence="ECO:0000250|UniProtKB:P05067"
FT   SITE            711..712
FT                   /note="Cleavage; by gamma-secretase; site 1"
FT                   /evidence="ECO:0000250|UniProtKB:P08592"
FT   SITE            713..714
FT                   /note="Cleavage; by gamma-secretase; site 2"
FT                   /evidence="ECO:0000250|UniProtKB:P05067"
FT   SITE            720..721
FT                   /note="Cleavage; by gamma-secretase; site 3"
FT                   /evidence="ECO:0000250|UniProtKB:P05067"
FT   SITE            739..740
FT                   /note="Cleavage; by a caspase"
FT                   /evidence="ECO:0000250|UniProtKB:P05067"
FT   MOD_RES         198
FT                   /note="Phosphoserine; by CK2"
FT                   /evidence="ECO:0000250|UniProtKB:P05067"
FT   MOD_RES         206
FT                   /note="Phosphoserine; by CK1"
FT                   /evidence="ECO:0000250|UniProtKB:P05067"
FT   MOD_RES         217
FT                   /note="Sulfotyrosine"
FT                   /evidence="ECO:0000255"
FT   MOD_RES         262
FT                   /note="Sulfotyrosine"
FT                   /evidence="ECO:0000255"
FT   MOD_RES         336
FT                   /note="Sulfotyrosine"
FT                   /evidence="ECO:0000255"
FT   MOD_RES         441
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:21183079"
FT   MOD_RES         497
FT                   /note="Phosphotyrosine"
FT                   /evidence="ECO:0000250|UniProtKB:P05067"
FT   MOD_RES         729
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0000250|UniProtKB:P08592"
FT   MOD_RES         730
FT                   /note="Phosphoserine; by APP-kinase I"
FT                   /evidence="ECO:0000250|UniProtKB:P08592"
FT   MOD_RES         743
FT                   /note="Phosphothreonine; by CDK5 and MAPK10 and LRRK2"
FT                   /evidence="ECO:0000269|PubMed:28720718"
FT   MOD_RES         757
FT                   /note="Phosphotyrosine; by ABL1"
FT                   /evidence="ECO:0000269|PubMed:11279131"
FT   CARBOHYD        542
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0007744|PDB:4YN0"
FT   CARBOHYD        571
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000305"
FT   DISULFID        38..62
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU01217"
FT   DISULFID        73..117
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU01217"
FT   DISULFID        98..105
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU01217"
FT   DISULFID        133..187
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU01217"
FT   DISULFID        144..174
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU01217"
FT   DISULFID        158..186
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU01217"
FT   DISULFID        291..341
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00031"
FT   DISULFID        300..324
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00031"
FT   DISULFID        316..337
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00031"
FT   CROSSLNK        763
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in ubiquitin)"
FT                   /evidence="ECO:0000250|UniProtKB:P08592"
FT   VAR_SEQ         289
FT                   /note="E -> V (in isoform APP695)"
FT                   /evidence="ECO:0000303|PubMed:11235921,
FT                   ECO:0000303|PubMed:1756177, ECO:0000303|PubMed:3322280"
FT                   /id="VSP_000012"
FT   VAR_SEQ         290..364
FT                   /note="Missing (in isoform APP695)"
FT                   /evidence="ECO:0000303|PubMed:11235921,
FT                   ECO:0000303|PubMed:1756177, ECO:0000303|PubMed:3322280"
FT                   /id="VSP_000013"
FT   VAR_SEQ         346..380
FT                   /note="Missing (in isoform APP751)"
FT                   /evidence="ECO:0000305"
FT                   /id="VSP_000014"
FT   MUTAGEN         728
FT                   /note="Y->A: No effect on MAPK8IP1 binding."
FT                   /evidence="ECO:0000269|PubMed:11517249"
FT   MUTAGEN         732..733
FT                   /note="HH->GL,GP: Almost complete loss of binding to G(o)
FT                   alpha subunit. No inhibition of GTPase activity."
FT   MUTAGEN         743
FT                   /note="T->E: No effect on MAPK8IP1 binding."
FT                   /evidence="ECO:0000269|PubMed:11517249"
FT   MUTAGEN         756
FT                   /note="G->F,H,N,S,W: Greatly impairs interaction with
FT                   DAB2."
FT                   /evidence="ECO:0000269|PubMed:11247302"
FT   MUTAGEN         756
FT                   /note="G->Y: Impairs interaction with DAB2."
FT                   /evidence="ECO:0000269|PubMed:11247302"
FT   MUTAGEN         757
FT                   /note="Y->F: Greatly promotes interaction with DAB2."
FT                   /evidence="ECO:0000269|PubMed:11247302,
FT                   ECO:0000269|PubMed:11517249"
FT   MUTAGEN         757
FT                   /note="Y->G,H,V: Greatly impairs interaction with DAB2."
FT                   /evidence="ECO:0000269|PubMed:11247302,
FT                   ECO:0000269|PubMed:11517249"
FT   MUTAGEN         757
FT                   /note="Y->G: No MAPK8IP1 nor APBA1 nor APBB1 nor DAB1
FT                   binding."
FT                   /evidence="ECO:0000269|PubMed:11247302,
FT                   ECO:0000269|PubMed:11517249"
FT   MUTAGEN         757
FT                   /note="Y->I,W: Impairs interaction with DAB2."
FT                   /evidence="ECO:0000269|PubMed:11247302,
FT                   ECO:0000269|PubMed:11517249"
FT   MUTAGEN         759
FT                   /note="N->A: No MAPK8IP1 nor APBA1 nor Dab1 binding. No
FT                   effect on APBB1 binding."
FT                   /evidence="ECO:0000269|PubMed:11247302,
FT                   ECO:0000269|PubMed:11517249"
FT   MUTAGEN         759
FT                   /note="N->G,L,M,P: Greatly impairs interaction with DAB2."
FT                   /evidence="ECO:0000269|PubMed:11247302,
FT                   ECO:0000269|PubMed:11517249"
FT   MUTAGEN         760
FT                   /note="P->E,F,I,K,L,Q,R,V,W,Y: Greatly impairs interaction
FT                   with DAB2."
FT                   /evidence="ECO:0000269|PubMed:11247302"
FT   MUTAGEN         762
FT                   /note="Y->A: No MAPK8IP1 nor APBA1 nor Dab1 binding. No
FT                   effect on APBB1 binding."
FT                   /evidence="ECO:0000269|PubMed:11247302,
FT                   ECO:0000269|PubMed:11517249"
FT   MUTAGEN         762
FT                   /note="Y->W: Greatly impairs interaction with DAB2."
FT                   /evidence="ECO:0000269|PubMed:11247302,
FT                   ECO:0000269|PubMed:11517249"
FT   CONFLICT        211
FT                   /note="G -> V (in Ref. 1; AAA37139)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        375
FT                   /note="V -> A (in Ref. 4; AAB41502)"
FT                   /evidence="ECO:0000305"
FT   TURN            47..49
FT                   /evidence="ECO:0007829|PDB:7MRN"
FT   STRAND          50..53
FT                   /evidence="ECO:0007829|PDB:7MRN"
FT   STRAND          56..58
FT                   /evidence="ECO:0007829|PDB:7MRN"
FT   HELIX           70..76
FT                   /evidence="ECO:0007829|PDB:7MRN"
FT   STRAND          82..87
FT                   /evidence="ECO:0007829|PDB:7MRN"
FT   STRAND          115..121
FT                   /evidence="ECO:0007829|PDB:7MRN"
FT   STRAND          127..129
FT                   /evidence="ECO:0007829|PDB:7MRN"
FT   STRAND          134..139
FT                   /evidence="ECO:0007829|PDB:7MRN"
FT   HELIX           147..160
FT                   /evidence="ECO:0007829|PDB:7MRN"
FT   STRAND          164..175
FT                   /evidence="ECO:0007829|PDB:7MRN"
FT   STRAND          178..187
FT                   /evidence="ECO:0007829|PDB:7MRN"
FT   HELIX           382..419
FT                   /evidence="ECO:0007829|PDB:4YN0"
FT   TURN            420..422
FT                   /evidence="ECO:0007829|PDB:4YN0"
FT   HELIX           425..481
FT                   /evidence="ECO:0007829|PDB:4YN0"
FT   HELIX           487..518
FT                   /evidence="ECO:0007829|PDB:4YN0"
FT   HELIX           520..550
FT                   /evidence="ECO:0007829|PDB:4YN0"
FT   HELIX           552..581
FT                   /evidence="ECO:0007829|PDB:4YN0"
FT   HELIX           744..753
FT                   /evidence="ECO:0007829|PDB:2ROZ"
SQ   SEQUENCE   770 AA;  86722 MW;  988D89E089092A3E CRC64;
     MLPSLALLLL AAWTVRALEV PTDGNAGLLA EPQIAMFCGK LNMHMNVQNG KWESDPSGTK
     TCIGTKEGIL QYCQEVYPEL QITNVVEANQ PVTIQNWCKR GRKQCKTHTH IVIPYRCLVG
     EFVSDALLVP DKCKFLHQER MDVCETHLHW HTVAKETCSE KSTNLHDYGM LLPCGIDKFR
     GVEFVCCPLA EESDSVDSAD AEEDDSDVWW GGADTDYADG GEDKVVEVAE EEEVADVEEE
     EADDDEDVED GDEVEEEAEE PYEEATERTT STATTTTTTT ESVEEVVREV CSEQAETGPC
     RAMISRWYFD VTEGKCVPFF YGGCGGNRNN FDTEEYCMAV CGSVSTQSLL KTTSEPLPQD
     PDKLPTTAAS TPDAVDKYLE TPGDENEHAH FQKAKERLEA KHRERMSQVM REWEEAERQA
     KNLPKADKKA VIQHFQEKVE SLEQEAANER QQLVETHMAR VEAMLNDRRR LALENYITAL
     QAVPPRPHHV FNMLKKYVRA EQKDRQHTLK HFEHVRMVDP KKAAQIRSQV MTHLRVIYER
     MNQSLSLLYN VPAVAEEIQD EVDELLQKEQ NYSDDVLANM ISEPRISYGN DALMPSLTET
     KTTVELLPVN GEFSLDDLQP WHPFGVDSVP ANTENEVEPV DARPAADRGL TTRPGSGLTN
     IKTEEISEVK MDAEFGHDSG FEVRHQKLVF FAEDVGSNKG AIIGLMVGGV VIATVIVITL
     VMLKKKQYTS IHHGVVEVDA AVTPEERHLS KMQQNGYENP TYKFFEQMQN
//
